You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥現代(600420.SH):山東朗諾將依託考昔片上市許可轉讓予國藥致君
格隆匯 07-28 17:59

格隆匯7月28日丨國藥現代(600420.SH)公吿,近日,公司控股子公司國藥集團致君(深圳)製藥有限公司(簡稱“國藥致君”)與山東朗諾製藥有限公司(簡稱“山東朗諾”)簽署了藥品上市許可轉讓有關合同,山東朗諾將依託考昔片(30mg、60mg)上市許可轉讓予國藥致君,並提供技術轉移服務。

本次交易標的為山東朗諾擁有的依託考昔片(30mg、60mg)。依託考昔片為新一代非甾體抗炎藥,鎮痛效果明確,胃腸道副作用小且不影響血小板功能。臨牀適用於治療骨關節炎急性期和慢性期的症狀和體徵、急性痛風性關節炎、原發性痛經等。

據悉,國藥致君尚需完成相關藥品的上市許可持有人變更,並將實施生產地址的變更。因各項事項的推進時間較長,存在不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account